These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37539406)

  • 1. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
    Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
    Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.
    Frączkiewicz J; Pawińska-Wąsikowska K; Szymbor K; Balwierz W; Skoczeń S; Czyżewski K; Kołtan S; Styczyński J; Małecka A; Irga-Jaworska N; Trelińska J; Młynarski W; Zając-Spychała O; Sobkowiak-Sobierajska A; Derwich K; Bal W; Chaber R; Książek A; Szczepański T; Zawitkowska J; Drabko K; Chodała-Grzywacz A; Karolczyk G; Kobierzycki C; Kałwak K
    J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610794
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
    Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
    Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
    Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
    Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
    [No Abstract]   [Full Text] [Related]  

  • 7. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
    Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
    Sciascia S; Rilat MLA; Fenoglio R; Foddai SG; Radin M; Cecchi I; Cinnirella G; Crosasso P; Guidetti MG; Barinotti A; Baldovino S; Menegatti E; Roccatello D
    Clin Kidney J; 2023 Sep; 16(9):1465-1468. PubMed ID: 37664578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
    You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
    Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
    Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
    Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
    Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
    Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Stein N; Saliba W
    Clin Infect Dis; 2023 Mar; 76(6):1067-1073. PubMed ID: 36310534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab + Cilgavimab: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(9):1001-1010. PubMed ID: 35727563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
    Jakimovski D; Eckert SP; Mirmosayyeb O; Thapa S; Pennington P; Hojnacki D; Weinstock-Guttman B
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
    Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
    Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
    Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients.
    Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N
    Med Clin (Barc); 2024 Sep; 163(6):275-280. PubMed ID: 38937218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.
    Lee YJ; Kim HK; Kim Y; Park SH; Lim JH; Jung J; Choi YS; Jo JC
    Ann Hematol; 2024 Jul; 103(7):2533-2539. PubMed ID: 38678486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.